No Data
No Data
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating
Leerink Partners analyst David Risinger maintains $Structure Therapeutics(GPCR.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 61.1% and a total average return
Buy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure Therapeutics
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler analyst Yasmeen Rahimi maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
No Data